Cargando…
Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) Apheresis
Background: The fulminant course of COVID-19, triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents with a high mortality rate and still lacks a causative treatment. C-reactive protein (CRP) has been shown to increase dramatically during the disease progression and corr...
Autores principales: | Esposito, Fabrizio, Matthes, Harald, Schad, Friedemann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999883/ https://www.ncbi.nlm.nih.gov/pubmed/35407564 http://dx.doi.org/10.3390/jcm11071956 |
Ejemplares similares
-
Case Report: C-Reactive Protein Apheresis in a Patient With COVID-19 and Fulminant CRP Increase
por: Ringel, Jens, et al.
Publicado: (2021) -
Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations
por: Kayser, Stefan, et al.
Publicado: (2020) -
Selective C‐reactive protein apheresis for Covid‐19 patients suffering from organ damage
por: Kayser, Stefan, et al.
Publicado: (2020) -
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV) Registry
por: Schumann, Christian, et al.
Publicado: (2022) -
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
por: Torzewski, Jan, et al.
Publicado: (2022)